Comment j’explore une myopathie inflammatoire ?

Selva-O’Callaghan, 2018, Classification and management of adult inflammatory myopathies, Lancet Neurol, 17, 816, 10.1016/S1474-4422(18)30254-0 Mariampillai, 2018, Development of a new classification system for idiopathic inflammatory myopathies based on clinical manifestations and myositis-specific autoantibodies, JAMA Neurol, 75, 1528, 10.1001/jamaneurol.2018.2598 Lundberg, 2017, 2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups, Arthritis Rheumatol, 69, 2271, 10.1002/art.40320 McGrath, 2018, Autoimmune myopathies: updates on evaluation and treatment, Neurotherapeutics, 15, 976, 10.1007/s13311-018-00676-2 Lundberg, 2016, Diagnosis and classification of idiopathic inflammatory myopathies, J Intern Med, 280, 39, 10.1111/joim.12524 Ghirardello, 2005, Anti-Mi-2 antibodies, Autoimmunity, 38, 79, 10.1080/08916930400022681 Narang, 2015, Cutaneous ulceration in dermatomyositis: association with anti-melanoma differentiation-associated gene 5 antibodies and interstitial lung disease, Arthritis Care Res, 67, 667, 10.1002/acr.22498 Dani, 2019, Anti-transcriptional intermediary factor 1 gamma antibodies in cancer-associated myositis: a longitudinal study, Clin Exp Rheumatol Fiorentino, 2013, Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1 gamma, Arthritis Rheum, 65, 2954, 10.1002/art.38093 Watanabe, 2016, Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy, J Neurol Neurosurg Psychiatry, 87, 1038, 10.1136/jnnp-2016-313166 Allenbach, 2018, Immune-Mediated Necrotizing Myopathies Working Group. 224th ENMC International Workshop: clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, Oct 14–16, 2016, Neuromuscul Disord, 28, 87, 10.1016/j.nmd.2017.09.016 Allenbach, 2014, Anti-HMGCR autoantibodies in European patients with autoimmune necrotizing myopathies: inconstant exposure to statin, Medicine, 93, 150, 10.1097/MD.0000000000000028 Pinal-Fernandez, 2017, Longitudinal course of disease in a large cohort of myositis patients with autoantibodies recognizing the signal recognition particle, Arthritis Care Res, 69, 263, 10.1002/acr.22920 Kao, 2004, Anti-signal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy, Arthritis Rheum, 50, 209, 10.1002/art.11484 Noguchi, 2017, Skeletal muscle involvement in antisynthetase syndrome, JAMA Neurol, 74, 992, 10.1001/jamaneurol.2017.0934 van der Meulen, 2003, Polymyositis: an overdiagnosed entity, Neurology, 61, 316, 10.1212/WNL.61.3.316 Herbert, 2016, Disease specificity of autoantibodies to cytosolic 5′-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases, Ann Rheum Dis, 75, 696, 10.1136/annrheumdis-2014-206691 Benveniste, 2014, Inclusion-body myositis, Rev Med Interne, 35, 472, 10.1016/j.revmed.2013.09.001 Anquetil, 2018, Immune checkpoint inhibitor-associated myositis, Circulation, 138, 743, 10.1161/CIRCULATIONAHA.118.035898 Tasca, 2015, Magnetic resonance imaging pattern recognition in sporadic inclusion-body myositis, Muscle Nerve, 52, 956, 10.1002/mus.24661 Kassardjian, 2015, Clinical features and treatment outcomes of necrotizing autoimmune myopathy, JAMA Neurol, 72, 996, 10.1001/jamaneurol.2015.1207 Damoiseaux, 2019, Autoantibodies in idiopathic inflammatory myopathies: clinical associations and laboratory evaluation by mono- and multispecific immunoassays, Autoimmun Rev, 18, 293, 10.1016/j.autrev.2018.10.004 Gordon, 2012, Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis, Cochrane Database Syst Rev, 8 Fasano, 2017, Rituximab in the treatment of inflammatory myopathies: a review, Rheumatology, 56, 26, 10.1093/rheumatology/kew146 Schmidt, 2017, Inclusion body myositis: advancements in diagnosis, pathomechanisms, and treatment, Curr Opin Rheumatol, 29, 632, 10.1097/BOR.0000000000000436 Benveniste, 2018, Rapamycin vs. placebo for the treatment of inclusion body myositis: improvement of the 6min walking distance, a functional scale, the fvc and muscle quantitative MRI, Arthritis Rheumatol, 69